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The MetaFrame system migration project at WorldPharma, while driven by merger and acquisition, had faced complexities 
caused by both technical challenges and organizational issues in the climate of uncertainties. However, WorldPharma still 
insisted on instigating this post-merger system migration project. This project served to (1) consolidate the separated legacy 
MetaFrame systems from the three pre-merger pharmaceutical organizations into one globally managed system and (2) 
develop a global support team for the newly consolidated global MetaFrame system. This system migration project was 
aligned with WorldPharma’s IT strategy that aimed to streamline its IT resources and enhance system efficiency. 
 





After the merger and acquisition (M&A) that involved 
WorldPharma acquiring and merging with CB Medicine and 
PharmaTech (we disguise the names of the three 
pharmaceutical companies in this case to protect their 
identities), a new department – the Computer and 
Information Technology (CIT) department, was established 
to globally manage the IT resources of the post-M&A 
WorldPharma organization. The CIT department initially 
served the main task of delineating the migration and 
integration plan for various IT systems, including the 
MetaFrame system, in this new organization.  
The main goals of the global MetaFrame system 
migration project were to (1) consolidate every legacy 
MetaFrame system from the three previously separated 
pharmaceutical companies into one unified, globally 
managed system; and (2) develop a global team for 
supporting the new and centralized MetaFrame system. A 
new manager – Mr. John Collins, was hired to manage this 
MetaFrame system migration project. Since this project was 
entangled with technical complexity and organizational 
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issues, Mr. Collins would have many obstacles to overcome 
(we disguise the names of the people in this case to protect 
their identities).  
 
1.1 Definition of MetaFrame  
Metaframe, a software product developed by Citrix 
Corporation, allows users to access the applications hosted 
on MetaFrame servers (running on UNIX or Windows 
operating systems). All applications are processed on these 
MetaFrame servers, enabling users with less powerful 
hardware to use resource intensive applications.  
Figure 1 shows a centralized structure of a MetaFrame 
system that includes an Independent Management 
Architecture datastore (IMA datastore), a Zone Data 
Collector (ZDC), and several MetaFrame servers. 
MetaFrame servers run the applications and allow users to 
access and use these applications. IMA datastore is a 
database (e.g., Microsoft Access, Microsoft SQL Server, 
Oracle, IBM DB2) that keeps the information about the 
configuration of the MetaFrame system. 
A MetaFrame system could increase its performance by 
setting up zones that allow geographic sites to operate on 
their local computer networks and minimize network 
communication to the IMA datastore. The logical way of 
establishing zones is to set up one in every operation that has 
a high number of MetaFrame servers or has a low capacity 
network connection to the nearest IMA datastore. For each 




Figure 1. MetaFrame Environment (centralized structure) 
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such as server loads, active sessions, and disconnected 
sessions. ZDC also manages the communication within the 
zone as an individual MetaFrame server will not directly 
query any other MetaFrame servers. 
It should be noted that Citrix Corporation had released 
several versions of its MetaFrame product, beginning with 
the first release titled “WinFrame” followed by “MetaFrame 
1.8” and “MetaFrame XP.” During this migration project, 
Citrix Corporation released a new version entitled 
“Presentation ServerTM” and also announced that the 
MetaFrame XP version would be supported until June 30, 
2007.  
Because there was a great deal of expertise on 
MetaFrame XP and a substantial MetaFrame XP presence 
within WorldPharma, it was agreed that MetaFrame XP 
would be implemented during this migration project even 
though the newer version (i.e., Presentation Server TM) had 
already been available. Thus, the MetaFrame mentioned in 
this teaching case would refer to the MetaFrame XP version. 
Additionally, during the time when this teaching case 
was written (i.e., on February 11, 2008), Citrix Corporation 
changed the name of its “Presentation Server™” product line 
to “XenApp™.” More detailed information about the 
MetaFrame product can be found at www.citrix.com.) 
 
1.2 Existing MetaFrame Systems: Pre-M&A  
Immediately after the M&A, a consolidation plan for various 
existing MetaFrame systems of the three legacy companies 
started to unfold. The first issue was related to the difference 
in MetaFrame structures implemented in the three legacy 
companies. The legacy MetaFrame systems of PharmaTech 
and CB Medicine adopted a “centralized” MetaFrame 
structure (see Figure 1). In contrast, the WorldPharma’s 
legacy MetaFrame systems implemented a “siloed” structure 
(see Figure 2).  
In the centralized structure, all users would access one 
large MetaFrame system environment controlled (logically) 
by the same IMA Datastore. For instance, a scientist in 
Sweden, an engineer in Japan, a manufacturing supervisor in 
the U.S., etc., would see and use the same MetaFrame 
system environment (please note that the MetaFrame system 
environment could be explained as “a list of servers and the 
applications hosted on each server”).  
On the other hand, in the siloed structure, each business 
unit (e.g., a marketing unit in East Coast US, a 
manufacturing unit in Midwest US) would build and 
maintain its own MetaFrame system environment. Thus, 
WorldPharma found itself with a marketing MetaFrame 
system environment, a manufacturing MetaFrame system 
environment, etc.  
In this regard, the CIT department and Mr. Collins 
would need to make a decision about which MetaFrame 
structure would match the main project goals and best 
support WorldPharma’s needs in competing in the 
pharmaceutical industry. 
 
2. PHARMACEUTICAL INDUSTRY 
 
2.1 New Drug Development 
Before a pharmaceutical company can introduce a new drug 
in the United States, it must receive an approval of a New 
Drug Application (NDA) from the Food and Drug 
Administration (FDA). As a document that may consist of 
over 100,000 pages, the NDA must provide enough 
information to permit the FDA to reach the following key 
decisions (www.fda.gov): 
• Whether the drug is safe and effective in its proposed 
use(s), and whether the benefits of the drug outweigh 
the risks. 
• Whether the drug's proposed labeling is appropriate, 
and what it should contain. 
• Whether the methods used in manufacturing the drug 
and the controls used to maintain the drug's quality are 
adequate to preserve the drug's identity, strength, 
quality, and purity. 
 
The process of bringing a new drug from the research 
stage to market takes many years and involves several phases 
(see Figure 3). After a chemical compound (i.e., a potential 
new drug) is synthesized, the compound proceeds to several 
years of preclinical testing, including animal testing and 
other testing (e.g., toxicology, pharmacokinetics) in the 
laboratories. The data generated in this preclinical testing 
provide the basis for the Investigational New Drug 
Application (IND), which the FDA must review and approve 
before clinical trials of the compound can begin. 
The three stages of clinical trials involve testing, in 
humans, for safety and for effectiveness in treating a target 
medical condition. Stage I involves less than 100 patients; 
Stage II involves a few hundred patients; and Stage III 
involves a few thousand patients. If the new chemical 
compound still appears to be promising after Stage III, the 
pharmaceutical company assembles the data generated 
during the clinical trials and other supporting materials into 
the NDA, which the FDA must approve before the new drug 
may appear in the market. 
After approval of the NDA, the pharmaceutical com-
pany is still required to monitor and gather safety data on the 
new drug. Reporting of Adverse Drug Reaction (ADR) data 
must be prepared for the FDA. The pharmaceutical company 
must report any “untoward effect that occurs in the course of 
use of a drug in professional practice” that is not listed on the 
drug label and that meets the definition of a serious ADR. If 
it turns out later that the new drug is not as safe as it was 
previously thought, the FDA may put strict requirements and 
limitations on the use of the new drug, or even revoke the 
right to sell it in the United States.  
Additionally, in pharmaceutical manufacturing, the 
pharmaceutical company must monitor the production 
process. This involves the process in which production oper-
ators must fill out forms to record data describing the con-
ditions for the manufacture of a particular batch of the drug. 
Furthermore, the NDA is not a static document. Even 
after the FDA has already approved it, the pharmaceutical 
company may submit additional information for further 
review when seeking approval for a broader range of 
therapeutic indications or in other circumstances. 
Finally, most drugs are on the market in more than one 
country, and the regulatory agencies of other nations must 
approve new drugs before they enter overseas markets. 
Those agencies often have requirements for forms and 
contents that are considerably different from those the FDA 
specifies for documents submitted to it. 
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Figure 3. New Drug Development Process  
(Studebaker, 1993) 
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Pharmaceutical companies have prospered historically 
by discovering, developing, manufacturing, and then 
marketing their drugs. To maintain their growth rates, 
pharmaceutical companies are increasing the number of 
potential new drugs being tested. However, the cost of 
developing new drugs is rising. Despite a dramatic increase 
in investment in technology in drug research and 
development (R&D), the gross productivity of drug R&D 
does not increase proportionally (Wilhelm, 2001). The 
Pharmaceutical Research and Manufacturers of America 
(www.pharma.org) said that it takes an average of 12-15 
years to discover and develop a new drug. Only 1 in 1000 
potential new drugs makes it to clinical trials. And only 1 of 
5 potential new drugs which make it to clinical trials actually 
makes it to market. This process makes the drug 
development cost be about $500 million for a new drug. 
 
2.2 IT in New Drug Development 
Because of the competition from a growing number of “me-
too” drugs, the pharmaceutical industry is highly 
competitive. There are several major pharmaceutical 
companies competing for the same market. The company 
that can design, test, and market a new drug first receives a 
tremendous competitive advantage, both in financial payback 
and brand recognition. As the patents are issued before a 
potential new drug goes into clinical trials, the faster a trial 
goes, the longer the pharmaceutical company enjoys a 
monopoly until generic versions can be sold (Marwaha, 
Patil, and Singh, 2007). 
Additionally, industry statistics highlight some other 
problems. An estimated 200 drug patents, (representing 
nearly $40 billion in annual revenue to the pharmaceutical 
industry) had expired by 2005. In 2003, the FDA approved 
only 17 potential new drugs, which was the lowest rate of 
approvals in 20 years (in 1996, the FDA approved 120 
potential new drugs). To be successful, pharmaceutical 
companies must respond by accelerating and increasing drug 
development.  
The clinical trial process is a key area that 
pharmaceutical companies are scrutinizing for efficiency and 
IT is critical to meeting this challenge. Pharmaceutical 
companies expect IT to improve data collection, speed up 
regulatory reporting, improve the targeting of physicians, 
and manage the progress of clinical trials. To boost the 
productivity of clinical trials, pharmaceutical companies 
have introduced Electronic Data Capture (EDC) systems, 
which allow patients, physicians, and researchers to prepare 
Case Report Forms (CRFs) and enter their trial information 
directly into the online systems. EDC systems have 
substantially reduced the time required to gather data on 
clinical trials – to 2 weeks, in some cases, from 20 weeks 
(Marwaha, Patil, and Singh, 2007).  
Regarding the FDA compliance, achieving cost 
effective FDA compliance is one of the industry’s most 
significant challenges. The risks associated with non-
compliance can be severe. A citation issued by the FDA for 
non-compliance can subject a company not only to large 
fines but also to a warning letter stating that if the infraction 
is not corrected within a given time period, product 
production will be curtailed by the order of the FDA. When a 
company has not properly documented changes to databases 
that store clinical trial data, the FDA has the authority to shut 
an entire production line down and/or withdraw products 
from the marketplace.  
An important aspect of FDA compliance is system 
validation, which means that all IT systems in the 
pharmaceutical company must be configured and 
documented (on an ongoing basis if changes are made) in 
accordance with regulatory guidelines. The FDA has also 
recognized the benefits of an electronic NDA system and has 
mandated that all NDAs be done electronically with some 
mechanisms in place to authenticate the person and the time 
of creation of electronic records. To comply with the 
Regulatory Compliance for Electronic Records and 
Electronic Signatures (i.e. Title 21 CFR Part 11) imposed by 
the FDA, technologies for generating and verifying the 
authenticity of operator control and observation have been 
developed. EDC systems include these technologies to 
develop and implement a procedure for verifying and 
documenting an individual’s identity before assigning an 
electronic signature (Mlodozeniec, 2004). 
In addition to the issue related to FDA Compliance, 
another issue exists. Unfortunately, many pharmaceutical 
companies are not coordinating a number of clinical trials 
across their organizations. The lack of cross-trial 
transparency can create delays when different clinical trials 
compete for scarce resources. Many pharmaceutical 
companies haven’t yet embraced reusability by streamlining 
their approach to the design of clinical trials. Certain 
components of the forms that guide researchers in clinical 
trials could be shared and reused across a number of them 
(Marwaha, Patil, and Singh, 2007). Thus, in recent years, 
some leading pharmaceutical companies have begun to 
increase productivity by revisiting IT systems to transform 
clinical trial design from ad hoc planning to an integrated 
approach. In this integrated approach, IT platforms for 
enterprise project management would play a major role to 
allow pharmaceutical companies to manage a portfolio of 
clinical trials more efficiently across the whole organization 
(Marwaha, Patil, and Singh, 2007). 
Finally, over the past decade, IT spending at most 
pharmaceutical companies has grown much faster than 
revenues, partly to meet the information needs of the 
business but mainly because the IT environment is diverse 
and highly decentralized (Marwaha and Van Kuiken, 2005). 
Most phases of drug development are divided into different 
business units or groups across countries with different 
cultures, languages, and regulations. The solutions to 
individual problems in drug development may be created or 
bought by individual groups. These have led to a highly 
fragmented and heterogeneous environment with several 
incompatible systems. In a typical pharmaceutical company, 
fiercely autonomous and well-financed divisions and 
functions make their own IT decisions. There might be 
dozens of different systems for Enterprise Resource Planning 
(ERP), finance, lab information management, and document 
management, etc. These layers and layers of fragmented 
systems make it very difficult for pharmaceutical companies 
to integrate and scale their IT resources to reach efficiency 
goals. This inefficiency is costly: more than 85% of the 
industry’s IT spending goes toward maintaining and 
supporting these disparate assets. In short, IT has become an 
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impediment to, rather than an enabler of, better business 
performance (Marwaha and Van Kuiken, 2005). 
 
3. WORLDPHARMA METAFRAME SYSTEM 
MIGRATION PROJECT 
 
3.1 Initiation and Planning 
For the CIT department, its main responsibility was to 
streamline IT resource management and save a significant 
amount of IT expenses on both equipment and personnel. 
WorldPharma’s IT resources would also include all existing 
MetaFrame systems from the three legacy organizations. 
After M&A, high expectations were poured onto the effort of 
consolidating all these existing MetaFrame systems into one 
globally managed system. Realizing the criticality and the 
benefits of the project, the executives at WorldPharma’s 
Global Project Management Office (GPMO) promptly 
approved this project. The GPMO also made an official 
announcement apropos of this project to all of its employees 
worldwide. According to GPMO, the project scope was 
pertaining to “… consolidate both local and regional 
MetaFrame systems into one globally managed system and 
to develop a global MetaFrame support team …”.  
After this official announcement, Mr. Collins, knowing 
that he would face an avalanche of challenges, wasted no 
time before refining the project scope, which encompassed 
the following project objectives: 
• To consolidate all MetaFrame systems from the three 
previously separated companies into one globally 
managed system. 
• To build fault tolerance for WorldPharma’s global 
MetaFrame system. 
• To retire those redundant MetaFrame servers and/or 
applications. 
• To employ standards (e.g., hardware components, 
operating systems) for every MetaFrame server. 
• To develop a global MetaFrame support team. 
• December 31, 2005 would be the project deadline 
(approximately 18 months after the official 
announcement). 
 
The project was planned for the existing MetaFrame 
systems at eight datacenters of the post-M&A WorldPharma 
organization (two centers in Michigan, one center in New 
Jersey, one center in New York, two centers in Connecticut, 
one center in Sweden, and one center in the U.K.).  
In this project, there would be three major activities: 
information gathering; planning of the new MetaFrame 
system environment; and decommissioning and migrating 
MetaFrame servers at each datacenter. Mr. Collins would 
need to collect, as much as possible, the information about 
the existing MetaFrame systems at each datacenter. Based on 
the collected information, a plan of the new global 
MetaFrame system and its system environment would be 
developed.  
Then, Mr. Collins, the existing IT and/or MetaFrame 
personnel, and the business units at each datacenter would 
discuss and develop a plan for the new MetaFrame system of 
the datacenter. This plan would include decisions regarding: 
• The applications that needed to be maintained on each 
MetaFrame server located at the datacenter 
• The applications that needed to be shut down, as users 
could be redirected to use the same or similar 
applications hosted on the servers located at other 
datacenters 
• The number of MetaFrame servers needed at the 
datacenter  
• The number of existing servers that did not meet the 
specified hardware and/or software standards, which 
would need to be decommissioned and then evaluated 
for potential re-build 
 
On deciding which applications and/or servers to be 
decommissioned, the first task required would be organizing 
all existing CB Medicine and PharmaTech business units to 
fit into the current WorldPharma governance structure. For 
example, when the legacy R&D division in PharmaTech was 
assimilated with the global R&D team of WorldPharma, it 
became relatively easy to decide which applications and/or 
servers needed to be decommissioned while dissolving the 
business units in PharmaTech (e.g., the R&D division).  
Another criterion was the redundant applications. For 
example, WorldPharma, CB Medicine, and PharmaTech all 
had a document management application running on their 
legacy MetaFrame servers; under this circumstance, the 
redundant applications of CB Medicine and PharmaTech 
were usually decommissioned. Finally, any business units 
that would like to retain any remaining applications had to 
develop a business case, to be presented to a steering 
committee, explaining why the applications should be 
retained. 
After developing a plan of the new MetaFrame system 
for each datacenter, the existing IT and/or MetaFrame 
personnel at each datacenter would (1) define their 
responsibilities, (2) set up the project team, and (3) begin the 
migration process. In this process, new MetaFrame servers 
would be brought into the datacenter, retired servers and 
applications would be shut down, remaining applications 
would be migrated to other servers, and retired servers would 
be evaluated for potential re-build. A timeline was set up for 
the migration at each datacenter, including (a) the time frame 
when the new servers would be ready for application 
installation and testing, (b) the date when the old servers 
would be disconnected and the applications would be moved 
over to other servers, and (c) the anticipated date to 
decommission the old servers.  
 
3.2 Potential Risks 
It was such a relief for the CIT department and Mr. Collins 
to learn that this MetaFrame system migration project 
received unwavering support from the executives at 
WorldPharma. The policy distributed to every WorldPharma 
business unit worldwide stipulated that the unified, globally 
managed MetaFrame system was one of the major objectives 
of WorldPharma’s IT strategy and that every business unit at 
each datacenter had to accomplish its MetaFrame system 
migration by December 31, 2005. Under this policy, 
potential risks related to project resistance and funding were 
mitigated.  
However, with high expectation from top management, 
the pressure to perform fell on Mr. Collins’ shoulders. “I 
must pull this off”, Mr. Collins murmured to himself as he 
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realized that the main potential risks of this project were 
technical-related risks. Because the existing MetaFrame 
servers hosted critical applications for business units’ daily 
operations (e.g., EDC, document management, financial 
management, supply chain management), thorough testing 
would be required to ensure compatibility and minimize any 
potential problems. Mr. Collins was also fully aware that a 
contingency plan would be needed in case of any migration 
failure.  
Another problem that Mr. Collins anticipated was that 
the project could suffer from a lack of information regarding 
some applications hosted on existing MetaFrame servers. 
Because of the M&A, some employees from virtually every 
business unit had already left WorldPharma. Unfortunately, 
several of these former employees were the individuals who 
were responsible for some of the applications hosted on 
MetaFrame servers. In one incident, an employee who was 
about to leave the company had not yet finished 
documenting one of the applications. When approached and 
asked about the documentation by Mr. Collins’ assistant, that 
employee just shrugged his shoulders expressing that he did 
not care. Amid the chaos, Mr. Collins tried to stay above the 
fray and thought about how to motivate those departing 
employees to finish their assignments before they left. 
Mr. Collins was also seriously concerned with the 
possibility of not having enough IT and/or MetaFrame 
personnel to complete the task of MetaFrame system 
migration on time. As one of the expected benefits from this 
project was saving significant amount of IT expenses on 
equipment and personnel, the number of IT and/or 
MetaFrame personnel in the company would eventually be 
reduced. Thus, some IT and/or MetaFrame personnel had 
already left WorldPharma to pursue other opportunities 
elsewhere and many others were looking for their new 
employment opportunities as well. Unfortunately, some of 
these former IT and/or MetaFrame personnel had built and 
maintained the legacy systems in the three previously 
separated organizations. Mr. Collins must devise a plan to 
ensure that there would be sufficient IT and/or MetaFrame 
personnel to finish the project on time. 
 
3.3 Global MetaFrame Support Team 
At the beginning of this MetaFrame system migration 
project, all existing MetaFrame personnel continued to 
support the applications and servers that they had supported 
before the M&A. However, as the migration continued and 
some servers and applications were relocated, the support 
and responsibilities were delegated to MetaFrame personnel 
based on geographical location. For example, if a server in 
Michigan was relocated to Connecticut, the MetaFrame 
personnel in Connecticut would become the primary support 
for this server even though the majority of the server’s users 
were still in Michigan and would move to Connecticut six 
months or a year later. 
Interestingly, Mr. Collins noticed that cohesiveness 
among the existing MetaFrame personnel emerged as a result 
of this assignment. As the servers and responsibilities were 
relocated, the existing MetaFrame personnel had to start 
exchanging more information in order to keep up with the 
increasing demands being placed upon them. They got to 
know each other better and had a chance to learn about 
various systems built around the world. “I am glad that they 
see eye to eye”, Mr. Collins gladly told his assistant as he 
realized that this was the first step for the MetaFrame 
support team to become truly global.  
Mr. Collins knew that member selection of the global 
MetaFrame support team would be based on several criteria 
including personality, documentation skills, technical and 
business knowledge, etc. However, there were still many 
decisions he had to make about this MetaFrame global 
support team. In global settings, users from different 
geographical locations and time zones could access the same 
applications at virtually the same time. Thus, for the support 
team to become truly global, Mr. Collins had to decide how 
many members of this global support team would be needed, 
where each team member should be located, and how this 
global support team should be managed etc., in order to 
effectively provide the 24/7 support for WorldPharma’s 
MetaFrame system regardless of its users’ geographical 
locations or time zones.  
 
4. RESULTS AND THE NEXT STEP 
 
In June 2006, approximately two years after its official 
announcement, WorldPharma’s MetaFrame system 
migration project was completed. It was about six months 
later than its expected completion date (i.e., December 31, 
2005). Additionally, total project cost was approximately 
10% higher than its original budget of $3.0M (including 
hardware and software, but excluding human resource 
compensation). Mr. Collins and his team had consolidated all 
existing MetaFrame systems (from the three previously 
separated companies) with multiple servers running the same 
or similar applications, into one globally managed 
MetaFrame system. The benefits of this MetaFrame system 
migration project were apparent. It was estimated that the 
costs of system hardware and software were reduced to 
approximately half of those previously spent by the three 
legacy companies combined. Additionally, the number of 
MetaFrame support personnel was also reduced from 
approximately 30 people to 13 people who are current 
members of the MetaFrame global support team.  
During 2006-2007, WorldPharma maximized the value 
of its global MetaFrame system by expanding the number of 
enterprise applications that were delivered using this global 
MetaFrame system. Similarly, in an ongoing effort of 
streamlining costs within WorldPharma’s IT organization 
and addressing the issues about infrastructure flexibility, the 
CIT department planned to deploy this global MetaFrame 
system for WorldPharma’s operation in several other 
countries. For example, WorldPharma previously 
implemented multiple servers running client/server 
applications across China. In an attempt to reduce the cost of 
updating and maintaining hardware for WorldPharma’s 
operation in China, the CIT department planned to 
consolidate the distributed servers in China into one 
MetaFrame system located in Beijing. The new MetaFrame 
system in Beijing would connect to, be an additional part of, 
employ the same copy of IMA datastore, and share the same 
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5. ASSIGNMENT QUESTIONS 
 
1. What are the advantages and the disadvantages of 
implementing the MetaFrame software system in 
WorldPharma? 
2. What are the advantages and the disadvantages of the 
“centralized” MetaFrame structure vs. the “siloed” 
MetaFrame structure in WorldPharma’s IT 
environment? Which one of these two structures should 
be implemented in this project? 
3. As the major stakeholders of this project, what were the 
main concerns of the business units, the existing 
MetaFrame support staff and other IT support 
personnel, and the CIT department (especially Mr. 
Collins)? 
4. Identify potential risks related to human resources in 
this project and provide your suggestion about what 
WorldPharma may do to manage these human resource 
risks. 
5. As MetaFrame servers hosted critical applications for 
business units, to shut down any old MetaFrame servers 
and put them into decommission process, it was 
necessary to have a consistent and comprehensive 
controlling procedure. Additionally, a contingency plan 
was required in case of any migration failure. Provide 
your suggestion regarding the procedure to shut down 
any old servers and the necessary contingency plan. 
6. Do you consider this MetaFrame system migration 
project a successful project? Provide reasons to justify 
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